Skip to main content

#153248

Pr8/22 Cell Line

Cat. #153248

Pr8/22 Cell Line

Cat. #: 153248

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 10-12 weeks

Organism: Mouse

Tissue: Lymphatic Tissue

Disease: Cancer

Model: Tumour line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Timothy Ward

Institute: Cancer Research UK Manchester Institute

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Pr8/22 Cell Line
  • Alternate name: Pr8/22; PR8/22; P388R
  • Cancers detailed: Drug resistant
  • Research fields: Cancer;Drug development;Genetics
  • Tool sub type: Continuous
  • Parental cell: P388
  • Organism: Mouse
  • Tissue: Lymphatic Tissue
  • Disease: Cancer
  • Growth properties: Suspension
  • Model: Tumour line
  • Conditional: No
  • Description: The cell line Pr8/22 also known as P388 Pr8/22 has been derived from P388 (an immortal murine acute leukaemia cell line). Pr8/22 is resistant to daunorubicin (anthracycline antibiotic) and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged. Pr8/22 proves valuable in studying mechanisms underlying anthracycline antibiotic resistance and for making predictive assessments of resistance patterns. 
  • Production details: The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm.
  • Cellosaurus id: CVCL_4276

Handling

  • Format: Frozen
  • Growth medium: Sub-culture routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.Culture Medium: RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1µM Daunorubicin.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Subculture routine: Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged.

References

  • McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597.
  • Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.